Status and phase
Conditions
Treatments
About
The objectives of the study are to assess the immunogenicity and safety of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.
Sex
Ages
Volunteers
Inclusion criteria
Male and female subjects will be eligible for participation in this study if they:
Exclusion criteria
Male and female subjects will be excluded from participation in this study if they:
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal